USD 80bn+ sales target increasingly derisked

Eurofins Scientific S.E: 2 directors

Two Directors at Eurofins Scientific S.E bought 4,430 shares at between 67.820EUR and 68.056EUR. The significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ...

ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 02/10/2026

ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 10/02/2026

AstraZeneca : 2026 guidance in line, AVANZAR trial postponed to H2

AstraZeneca : Guidance 2026 en ligne, l’essai AVANZAR est décalé au S2

AstraZeneca PLC: Collaboration with CSPC strengthens weight-management...

AstraZeneca will pay $1.2 billion upfront, with up to $3.5 billion in milestones. The deal broadens its position in the obesity-care market with little immediate effect on its credit quality

EDP-Energias De Portugal S.A: 1 director

A director at EDP-Energias De Portugal S.A bought 3,891,563 shares at 4.145EUR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...

Munchener Ruckversicherungs-Gesellschaft AG: 1 director

A director at Munchener Ruckversicherungs-Gesellschaft AG sold 898 shares at 520.267EUR and the significance rating of the trade was 86/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...

AstraZeneca PLC - September 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Thematic - 2026 Outlook - "5 More Years" (55pgs)

For access to the full note, please contact Naresh Chouhan ( ) With EU Pharma (ex-Novo) now having reached decade high valuations vs EuroStoxx600, we believe the sector has broken out & the sustainability of the growth profile will now generate continued strong performance. Consensus 5yr sales & EPS CAGR’s stand at 4% & 7% for 15x 2026 PE. We show there is upside to this from underestimated pipelines where cons. rarely fully models “monster” drugs & from M&A which we expect to be strong at JPM ...

ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 12/12/2025

ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 12/12/2025

Munich Re : Pushing for growth in non-cyclical business lines and over...

INFORME DIARIO 11 DICIEMBRE (ANÁLISIS BANCO SABADELL)

COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: CAF, INDRA, NATURGY. EUROPA: MUNICH RE. La FED cumple con el recorte de tipos Con el Ibex manteniéndose cerca de sus máximos las bolsas europeas continuaron una jornada más con cierta indefinición a la espera de catalizadores. En el STOXX 600, los mejores sectores fueron R. Básicos y Bancos mientras que Autos y Construcción (afectado por la rebaja de recomendación a Vinci por parte de una casa de análisis) fueron los que más cayeron. Por el lado m...

AstraZeneca: 1 director

A director at AstraZeneca sold 7,500 shares at 177.269USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 11/12/2025

ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 12/11/2025

Munich Re : Q3 2025 with strong underlying profitability but adverse v...

MUNICH RE: RDOS. 3T’25 (ANÁLISIS BANCO SABADELL)

Rdos. 3T'25 vs 3T'24: Primas: 14.575 M euros (-5,9% vs +1,5% BS(e) y +1,3% consenso); Rdo. Operativo: 3.036 M euros (+136,3% vs +103,3% BS(e) y +123,8% consenso); BDI: 1.997 M euros (+104,0% vs +74,0% BS(e) y +96,7% consenso). Rdos. 9meses'25 vs 9meses'24: Primas: 45.161 M euros (-0,8% vs +1,8% BS(e) y +1,7% consenso); Rdo. Operativo: 7.204 M euros (-6,8% vs -11,9% BS(e) y -8,8% consenso); BDI: 5.176 M euros (-8,7% vs -13,9% BS(e) y -10,0% consenso).